Sun Exposure and Vitamin D Are Independent Risk Factors for CNS Demyelination
Authors
Affiliations
Objectives: To examine whether past and recent sun exposure and vitamin D status (serum 25-hydroxyvitamin D [25(OH)D] levels) are associated with risk of first demyelinating events (FDEs) and to evaluate the contribution of these factors to the latitudinal gradient in FDE incidence in Australia.
Methods: This was a multicenter incident case-control study. Cases (n = 216) were aged 18-59 years with a FDE and resident within one of 4 Australian centers (from latitudes 27°S to 43°S), from November 1, 2003, to December 31, 2006. Controls (n = 395) were matched to cases on age, sex, and study region, without CNS demyelination. Exposures measured included self-reported sun exposure by life stage, objective measures of skin phenotype and actinic damage, and vitamin D status.
Results: Higher levels of past, recent, and accumulated leisure-time sun exposure were each associated with reduced risk of FDE, e.g., accumulated leisure-time sun exposure (age 6 years to current), adjusted odds ratio (AOR) = 0.70 (95% confidence interval [CI] 0.53-0.94) for each ultraviolet (UV) dose increment of 1,000 kJ/m(2) (range 508-6,397 kJ/m(2)). Higher actinic skin damage (AOR = 0.39 [95% CI 0.17-0.92], highest grade vs the lowest) and higher serum vitamin D status (AOR = 0.93 [95% CI 0.86-1.00] per 10 nmol/L increase in 25(OH)D) were independently associated with decreased FDE risk. Differences in leisure-time sun exposure, serum 25(OH)D level, and skin type additively accounted for a 32.4% increase in FDE incidence from the low to high latitude regions.
Conclusions: Sun exposure and vitamin D status may have independent roles in the risk of CNS demyelination. Both will need to be evaluated in clinical trials for multiple sclerosis prevention.
Al-Shammri S, Chattopadhyay A, Mustafa A Front Neurol. 2025; 16:1455779.
PMID: 39990260 PMC: 11842254. DOI: 10.3389/fneur.2025.1455779.
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis.
Chang G, Sebastian P, Virupakshaiah A, Schoeps V, Cherbuin N, Casper T Neurol Neuroimmunol Neuroinflamm. 2025; 12(2):e200375.
PMID: 39938013 PMC: 11820808. DOI: 10.1212/NXI.0000000000200375.
Alelyani M, Gameraddin M, Alshahrani R, Alaslami W, Sarhan R, Alghamdi S Medicine (Baltimore). 2024; 103(22):e38369.
PMID: 39259102 PMC: 11142836. DOI: 10.1097/MD.0000000000038369.
Li B, Zhang L, Li Q, Zhang J, Wang W, Quan J PLoS One. 2024; 19(8):e0308815.
PMID: 39163298 PMC: 11335101. DOI: 10.1371/journal.pone.0308815.
Zhu Y, Zhou X, Jia J, Xue Q Neurol Sci. 2024; 45(5):2379-2381.
PMID: 38175315 DOI: 10.1007/s10072-023-07290-x.